Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Metronidazole in Infants with Bowel Habit Change: Irrelative to the Clostridium difficile Colonization

  • Kim, Eun Jin (Department of Pediatrics, Gachon University Gil Medical Center) ;
  • Lee, Sung Hyun (Department of Pediatrics, Gachon University Gil Medical Center) ;
  • Tchah, Hann (Department of Pediatrics, Gachon University Gil Medical Center) ;
  • Ryoo, Eell (Department of Pediatrics, Gachon University Gil Medical Center)
  • Received : 2016.06.21
  • Accepted : 2016.09.29
  • Published : 2017.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Clinical symptoms associated with Clostridium difficile infection (CDI) can vary widely. Carrier state without apparent symptoms is relatively common during infancy. The objective of this study was to determine the association of C. difficile colonization with bowel habit change and the effect of C. difficile colonization treatment on restoration of normal bowel habit. Methods: Between 2006 and 2014, infants at 1 to 12 months of age with diarrhea for more than 2 weeks who did not improve with conservative care were recruited from Gachon University Gil Medical Center. Infants who were followed up for at least 7 days were included. The presence or absence of C. difficile colonization, effect of metronidazole, and other medical records were reviewed. To determine the association between CDI and bowel habit change, logistic regression analysis was used. Results: Of a total of 126 infants, 74 (58.7%) were male patients. Of the 126 patients, 27 (21.4%) had C. difficile colonization. Significant (p<0.05) risk factors for C. difficile colonization included artificial milk feeding (odds ratio [OR], 4.310; 95% confidence interval [CI], 1.564-11.878), prior rotavirus vaccination (OR, 4.322; 95% CI, 1.018-18.349), and antibiotic use (OR, 4.798; 95% CI, 1.430-16.101). There was improvement in bowel habit after metronidazole therapy (OR, 0.34; 95% CI, 0.15-0.79; p<0.05), regardless of the presence or absence of C. difficile colonization, Conclusion: There was no significant correlation between bowel habit change and C. difficile colonization during infancy. However, metronidazole can be used as an optional method to manage functional gastrointestinal disorders.

Keywords

References

  1. Pezzella V, De Martino L, Passariello A, Cosenza L, Terrin G, Berni Canani R. Investigation of chronic diarrhoea in infancy. Early Hum Dev 2013;89:893-7. https://doi.org/10.1016/j.earlhumdev.2013.08.007
  2. Langley JM, LeBlanc JC, Hanakowski M, Goloubeva O. The role of Clostridium difficile and viruses as causes of nosocomial diarrhea in children. Infect Control Hosp Epidemiol 2002;23:660-4. https://doi.org/10.1086/501990
  3. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122:1266-70. https://doi.org/10.1542/peds.2008-0469
  4. Sammons JS, Toltzis P, Zaoutis TE. Clostridium difficile infection in children. JAMA Pediatr 2013;167:567-73. https://doi.org/10.1001/jamapediatrics.2013.441
  5. Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med 2015;372:1539-48. https://doi.org/10.1056/NEJMra1403772
  6. Rousseau C, Poilane I, De Pontual L, Maherault AC, Le Monnier A, Collignon A. Clostridium difficile carriage in healthy infants in the community: a potential reservoir for pathogenic strains. Clin Infect Dis 2012;55:1209-15. https://doi.org/10.1093/cid/cis637
  7. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62. https://doi.org/10.1056/NEJM199401273300406
  8. Schutze GE, Willoughby RE. Clostridium difficile infection in infants and children. Pediatrics 2013;131:196-200. https://doi.org/10.1542/peds.2012-2992
  9. Sandora TJ, Fung M, Flaherty K, Helsing L, Scanlon P, Potter-Bynoe G, et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J 2011;30:580-4. https://doi.org/10.1097/INF.0b013e31820bfb29
  10. Rasquin-Weber A, Hyman PE, Cucchiara S, Fleisher DR, Hyams JS, Milla PJ, et al. Childhood functional gastrointestinal disorders. Gut 1999;45 Suppl 2:II60-8.
  11. Almeida R, Gerbaba T, Petrof EO. Recurrent Clostridium difficile infection and the microbiome. J Gastroenterol 2016;51:1-10. https://doi.org/10.1007/s00535-015-1099-3
  12. Rineh A, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR. Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther 2014;12:131-50. https://doi.org/10.1586/14787210.2014.866515
  13. Rousseau C, Levenez F, Fouqueray C, Dore J, Collignon A, Lepage P. Clostridium difficile colonization in early infancy is accompanied by changes in intestinal microbiota composition. J Clin Microbiol 2011;49:858-65. https://doi.org/10.1128/JCM.01507-10
  14. Benson L, Song X, Campos J, Singh N. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007;28:1233-5. https://doi.org/10.1086/520732
  15. Cohen MB. Clostridium difficile infections: emerging epidemiology and new treatments. J Pediatr Gastroenterol Nutr 2009;48 Suppl 2:S63-5. https://doi.org/10.1097/MPG.0b013e3181a118c6
  16. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl 1:S19-31. https://doi.org/10.1086/521859
  17. Benno Y, Sawada K, Mitsuoka T. The intestinal microflora of infants: composition of fecal flora in breast-fed and bottle-fed infants. Microbiol Immunol 1984;28:975-86. https://doi.org/10.1111/j.1348-0421.1984.tb00754.x
  18. Rolfe RD, Song W. Immunoglobulin and non-immunoglobulin components of human milk inhibit Clostridium difficile toxin A-receptor binding. J Med Microbiol 1995;42:10-9. https://doi.org/10.1099/00222615-42-1-10
  19. Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904. https://doi.org/10.1152/physrev.00045.2009
  20. Ang L, Arboleya S, Lihua G, Chuihui Y, Nan Q, Suarez M, et al. The establishment of the infant intestinal microbiome is not affected by rotavirus vaccination. Sci Rep 2014;4:7417.
  21. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007;102:2047-56; quiz 2057. https://doi.org/10.1111/j.1572-0241.2007.01275.x
  22. Mezoff EA, Cohen MB. Acid suppression and the risk of Clostridium difficile infection. J Pediatr 2013;163:627-30. https://doi.org/10.1016/j.jpeds.2013.04.047
  23. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95. https://doi.org/10.1001/jama.294.23.2989
  24. Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis 2015;60 Suppl 2:S122-8. https://doi.org/10.1093/cid/civ138
  25. Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012;157:878-88. https://doi.org/10.7326/0003-4819-157-12-201212180-00563
  26. Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013;382:1249-57. https://doi.org/10.1016/S0140-6736(13)61218-0
  27. Na JY, Park JM, Lee KS, Kang JO, Oh SH, Kim YJ. Clinical characteristics of symptomatic Clostridium difficile infection in children: conditions as infection risks and whether probiotics is effective. Pediatr Gastroenterol Hepatol Nutr 2014;17:232-8. https://doi.org/10.5223/pghn.2014.17.4.232
  28. Pant C, Deshpande A, Altaf MA, Minocha A, Sferra TJ. Clostridium difficile infection in children: a comprehensive review. Curr Med Res Opin 2013;29:967-84. https://doi.org/10.1185/03007995.2013.803058
  29. Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011;365:1693-703. https://doi.org/10.1056/NEJMoa1012413
  30. Hung YP, Lee JC, Lin HJ, Liu HC, Wu YH, Tsai PJ, et al. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect 2015;48:241-8. https://doi.org/10.1016/j.jmii.2014.04.011
  31. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome--a meta-analysis. Am J Gastroenterol 2006;101:1894-9. https://doi.org/10.1111/j.1572-0241.2006.00654.x
  32. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535-44. https://doi.org/10.1111/j.1365-2036.2007.03399.x
  33. Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology 2016. pii: S0016-5085(16)34926-5. doi: 10.1053/j.gastro.2016.08.003. [Epub ahead of print]
  34. Perez-Cobas AE, Artacho A, Ott SJ, Moya A, Gosalbes MJ, Latorre A. Structural and functional changes in the gut microbiota associated to Clostridium difficile infection. Front Microbiol 2014;5:335.